Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus low-dose fluconazole for primary prevention of Candida infections in hematologic malignancies
IRCT20140818018842N37Phase 3Completed
- Sponsor
- Hematology, Oncology and Stem Cell Transplantation Research Center
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of fluconazole in candidiasis, Candidal colonization, dermatomycosis and 1 more (2 arms), sponsored by Hematology, Oncology and Stem Cell Transplantation Research Center. Primary endpoint: Occurrence of candidal infections. Started Dec 2023; status: completed.
02
Drugs
fluconazole
03
Conditions
candidiasisCandidal colonizationdermatomycosismycoses
Beyond the preview
Go deeper on IRCT20140818018842N37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N37.